Stock Market & Financial Investment News

News Breaks June 30, 2012 11:13 EDT BMY, AMLN Bristol-Myers to acquire Amylin for $31 per share, $5.3B Bristol-Myers Squibb Company (BMY) and Amylin Pharmaceuticals (AMLN) announced that Bristol-Myers Squibb will acquire Amylin for $31 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3B. The total value of the transaction, including Amylin’s net debt and a contractual payment obligation to Eli Lilly & Company, together totaling about $1.7B, is approximately $7B. The acquisition has been unanimously approved by the boards of directors of Bristol-Myers Squibb and Amylin. The board of directors of Amylin has unanimously recommended that Amylin’s stockholders tender their shares into the tender offer. The companies expect the tender offer to close approximately thirty days after commencement of the tender offer. News For BMY;AMLN From The Last 14 Days Check below for free stories on BMY;AMLN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 13:21 EDT BMY Options with increasing implied volatility: CPRT BMY GDI HNZ Subscribe for More Information May 16, 2013 16:32 EDT BMY Bristol-Myers announces intention to voluntarily delist preferred stock Subscribe for More Information 13:20 EDT BMY Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. 13:14 EDT BMY Bristol-Myers upgraded to Outperform from Market Perform at Leerink Subscribe for More Information 08:55 EDT BMY BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information 08:38 EDT BMY Bristol-Myers shares likely to give back recent gains, says Leerink Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. 05:52 EDT BMY Stocks with implied volatility movement; BMY SLV Subscribe for More Information May 15, 2013 11:28 EDT BMY Options with increasing implied volatility: BMY AGNC EBIX IAU Subscribe for More Information 09:43 EDT BMY Active equity option families trading on open Subscribe for More Information May 14, 2013 07:24 EDT BMY EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 10, 2013 11:48 EDT BMY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information May 9, 2013 10:17 EDT BMY Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information May 8, 2013 10:33 EDT BMY Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday. May 6, 2013 17:03 EDT BMY Bristol-Myers, Pfizer announce publication of ARISTOTLE trial Bristol-Myers Squibb (BMY) and Pfizer (PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. Based on the results of the subanalysis, the benefits of Eliquis compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers' and patients' quality of INR control. 08:53 EDT BMY BofA/Merrill's major pharma analysts hold an analyst/industry conference call Subscribe for More Information 07:27 EDT BMY Bristol-Myers, AstraZeneca announces results of metreleptin study Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.